The REXULTI® (brexpiprazole) Savings Card offers two separate benefits: REXULTI as well as a generic ANTIDEPRESSANT*

What the REXULTI Savings Card covers:

REXULTI
Two Months of REXULTI as little as
$0
REXULTI Refills as little as
$5
90-day Prescription as little as
$5
 
Generic ANTIDEPRESSANT
Covered Generic
ANTIDEPRESSANTS
as little as
(for up to 12 uses)
$0
 
REXULTI Savings Card
Phone icon

Your eligible patients can text SAVE to 96747 to get their REXULTI Savings Card today.

*For eligible commercially insured patients who are prescribed REXULTI. Benefits apply to copays, co-insurance, and pharmacy deductibles. Up to $8,180 applied to your patient's annual deductible with up to 12 uses.a

Terms and conditions apply.

Message and data rates apply. Message frequency varies. Text HELP for help and STOP to opt-out. Otsuka may use pharmacy information to provide refill reminders with consent.
See REXULTIsavings.com for privacy policy.

Terms, Conditions, and Eligibility Criteria: This program is offered by Otsuka America Pharmaceutical, Inc. and applies only to valid REXULTI® (brexpiprazole) and/or eligible generic prescriptions. Eligible insured patients will pay as little as $0 for first two uses 8-33 and 34-60-day supply and as little as $5 for 90-day supply. On subsequent uses 3 and beyond, patients will pay as little as $5 and receive a maximum savings up to $1,200. For eligible generic prescription with 30-day supply patient will pay as little as $0 and receive savings up to $100 per 30-day supply. Up to $8,180 applied to your patient’s annual deductible with up to 12 uses. Limit 1 card per patient.

Restrictions: Offer is not transferable. Patients must have commercial drug insurance and a prescription consistent with FDA-approved product labeling. Patients are not eligible if they are covered in whole or in part by any state program or federal healthcare program, including, but not limited to, Medicare or Medicaid (including Medicaid managed care), Medigap, VA, DOD, or TRICARE. For eligible generic prescription, patient must be 18 years of age or older. Only valid in U.S. and Puerto Rico. Offer void where prohibited by law, taxed, or restricted. Other restrictions may apply. This program is not health insurance. Otsuka America Pharmaceutical, Inc. has the right to rescind, revoke, or amend this program at any time without notice. Your participation in this program confirms that this offer is consistent with your insurance coverage and that you will report the value received if required by your insurance provider. When you use this card, you are certifying that you understand and will comply with the program rules, terms, and conditions. Offer not valid for cash-paying patients OR where drug is not covered by the primary insurance.

REXULTI has broad national coverage and affordability support

97% of patients nationally have coverage for REXULTI icon.

OF PATIENTS NATIONALLY

have COVERAGE for REXULTI 1

*The total of prescriptions referenced is [XX%]. Of the total prescriptions, covered without restrictions represents [XX%] of prescriptions, prior authorization represents an additional [XX%] of prescriptions, and step edit represents an additional [XX%] of prescriptions as defined in footnotes ¶, §, ‖. Managed Markets Insight & Technology, LLC database as of [Month YYYY] and IMS Xponent PlanTrak data as of [Month YYYY].

Your local area is determined as the geography associated with all ZIP codes around you that have the same first three digits.

Please note that plans may have multiple formularies, and they are subject to change by the plan. Please check with the health plan directly to confirm formulary status, requirements, and coverage information for individual patients.

Covered without restrictions includes health plans with prior authorization requirements that are consistent with REXULTI® (brexpiprazole) Prescribing Information and also establish the appropriate patient. Patients associated with plans that implement only these types of requirements are not considered restricted.

§Prior Authorization is defined as an approach to prescription drug management where specific criteria are required, as determined by the health plan, to be met before receiving access to a drug originally prescribed.

Step edit is defined as an approach to prescription drug management where patients are required to try one or more drug therapies before receiving access to a drug originally prescribed.

Data provided here do not guarantee coverage or payment (partial or full). Actual benefits are determined by respective plan administrators. Consult with payer for all relevant coverage requirements.

Coverage Support

IMPORTANT SAFETY INFORMATION
and INDICATIONS

 
  • Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults
  • Treatment of schizophrenia in adults and pediatric patients ages 13 years and older
  • Treatment of agitation associated with Alzheimer’s dementia (AAD)
ISI Block Title

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death. REXULTI is not approved for the treatment of patients with dementia-related psychosis without agitation associated with dementia due to Alzheimer’s disease.

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

Antidepressants increased the risk of suicidal thoughts and behaviors in patients aged 24 years and younger. Monitor for clinical worsening and emergence of suicidal thoughts and behaviors. The safety and effectiveness of REXULTI have not been established in pediatric patients with MDD.

Contraindication: In patients with known hypersensitivity to brexpiprazole or any of its components. Reactions have included: rash, facial swelling, urticaria and anaphylaxis.

Cerebrovascular Adverse Events, Including Stroke: In clinical trials, elderly patients with dementia randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. REXULTI is not approved for the treatment of patients with dementia-related psychosis without agitation associated with dementia due to Alzheimer’s disease.

Neuroleptic Malignant Syndrome (NMS): NMS is a potentially fatal symptom complex reported in association with administration of antipsychotic drugs, including REXULTI. Clinical signs of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Manage NMS with immediate discontinuation of REXULTI, intensive symptomatic treatment, and monitoring.

Tardive Dyskinesia (TD): Risk of TD, and the potential to become irreversible, appear to increase with duration of treatment and total cumulative dose of antipsychotic drugs. TD can develop after relatively brief treatment periods, at low doses, or after discontinuation of treatment. For chronic treatment, use the lowest dose and shortest duration of REXULTI needed to produce a clinical response. If signs and symptoms of TD appear, drug discontinuation should be considered.

Metabolic Changes: Atypical antipsychotic drugs, including REXULTI, have caused metabolic changes including:

  • Hyperglycemia/Diabetes Mellitus: Hyperglycemia and diabetes mellitus, in some cases extreme and associated with diabetic ketoacidosis, hyperosmolar coma or death, have been reported in patients treated with atypical antipsychotics. Assess fasting plasma glucose before or soon after initiation of antipsychotic medication and monitor periodically during long-term treatment.
  • Dyslipidemia: Atypical antipsychotics cause adverse alterations in lipids. Before or soon after initiation of antipsychotic medication, obtain a fasting lipid profile at baseline and monitor periodically during treatment.
  • Weight Gain: Weight gain has been observed in patients treated with REXULTI. Monitor weight at baseline and frequently thereafter.

Pathological Gambling and Other Compulsive Behaviors: Intense urges, particularly for gambling, and the inability to control these urges have been reported while taking REXULTI. Other compulsive urges have been reported less frequently. Prescribers should ask patients or their caregivers about the development of new or intense compulsive urges. Consider dose reduction or stopping REXULTI if such urges develop.

Leukopenia, Neutropenia, and Agranulocytosis: Leukopenia and neutropenia have been reported with antipsychotics. Agranulocytosis (including fatal cases) has been reported with other agents in this class. Monitor complete blood count in patients with pre-existing low white blood cell count (WBC)/absolute neutrophil count or history of drug-induced leukopenia/neutropenia. Discontinue REXULTI at the first sign of a clinically significant decline in WBC and in patients with severe neutropenia.

Orthostatic Hypotension and Syncope: Atypical antipsychotics cause orthostatic hypotension and syncope. Generally, the risk is greatest during initial dose titration and when increasing the dose. Monitor in patients vulnerable to hypotension, and those with cardiovascular and cerebrovascular diseases.

Falls: Antipsychotics may cause somnolence, postural hypotension, motor, and sensory instability, which may lead to falls causing fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating treatment and recurrently during therapy.

Seizures: REXULTI may cause seizures and should be used with caution in patients with a history of seizures or with conditions that lower the seizure threshold.

Body Temperature Dysregulation: Use REXULTI with caution in patients who may experience conditions that increase body temperature (e.g., strenuous exercise, extreme heat, dehydration, or concomitant use with anticholinergics).

Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotics, including REXULTI, and should be used with caution in patients at risk for aspiration.

Potential for Cognitive and Motor Impairment: REXULTI has the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including operating motor vehicles, until they are reasonably certain REXULTI does not affect them adversely.

Concomitant Medication: Dosage adjustments are recommended in patients who are known cytochrome P450 (CYP) 2D6 poor metabolizers and in patients taking concomitant CYP3A4 inhibitors or CYP2D6 inhibitors or strong CYP3A4 inducers.

Most commonly observed adverse reactions: In clinical trials of adults, the most common adverse reactions were:

  • Major Depressive Disorder (MDD) (adjunctive treatment to antidepressant therapy; ≥5% incidence and at least twice the rate of placebo for REXULTI vs. placebo): weight increased, somnolence, and akathisia.
  • Schizophrenia (≥4% incidence and at least twice the rate of placebo for REXULTI vs. placebo): weight increased. Adverse reactions in patients 13 to 17 years of age were generally similar to those observed in adult patients.
  • Agitation associated with dementia due to Alzheimer’s disease (≥4% incidence and at least twice the rate of placebo for REXULTI vs. placebo): nasopharyngitis and dizziness.

Dystonia: Symptoms of dystonia may occur in susceptible individuals during the first days of treatment and at low doses.

Pregnancy: Adequate and well-controlled studies to assess the risks of REXULTI during pregnancy have not been conducted. REXULTI should be used during pregnancy only if the benefit justifies the risk to the fetus.

Lactation: It is not known if REXULTI is excreted in human breast milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

INDICATIONS

REXULTI is indicated for:

  • Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults
  • Treatment of schizophrenia in adults and pediatric patients ages 13 years and older
  • Treatment of agitation associated with dementia due to Alzheimer’s disease

Limitations of Use: REXULTI is not indicated as an as needed (“prn”) treatment for agitation associated with dementia due to Alzheimer’s disease

Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING.